Paolo Strati, MD
Paolo Strati MD is currently an Assistant Professor, Term Tenure Track, in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, TX. He is also the Clinical Director for the Lymphoma Tissue Bank, and previously served as Assistant Professor at the Mayo Clinic, in Rochester (MN).
Dr. Strati earned his medical degree cum laude from the San Raffaele University of Milan (Italy) in 2008, and completed an Internal Medicine Residency at the same institution and, subsequently, at the Mayo Clinic, in Rochester (MN). He also completed a Hematology-Oncology Fellowship at MD Anderson Cancer Center, a Leukemia and Lymphoma fellowship at the same institution, and a Malignant Hematology fellowship at the Barts Cancer Institute, in London (UK).
Dr. Strati is an internationally recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic. He is author of several peer-reviewed manuscripts published on high impact journal, including Blood and Lancet Haematology, and he is regularly invited to present his work at international scientific meetings, including the American Society of Hematology and the American Society of Clinical Oncology conference. In light of his research accomplishments, he has received multiple grants and awards, including the Lymphoma Research Foundation Career Development Award and the Conquer Cancer Foundation Young Investigator Award.
Dr. Strati is committed to gain further insight into the biology of the lymphoma immune microenvironment, and to manipulate its components successfully, in order to develop novel effective therapies and to decrease the toxicity of treatment strategies already available for patients with B-cell lymphoma.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstrazenecaDate added:03/28/2023Date updated:05/21/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Kite-GileadDate added:03/28/2023Date updated:05/21/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ADC TherapeuticsDate added:03/28/2023Date updated:05/21/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Roche GenentechDate added:03/28/2023Date updated:05/21/2024